Karyopharm Therapeutics Share Price Today
(NASDAQ: KPTI)

Name: Karyopharm Therapeutics Share Price Today (NASDAQ: KPTI) - Karyopharm Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Karyopharm Therapeutics share price is $6.18 & ₹537.47 as on 6 Mar 2025, 2.30 'hrs' IST

$6.18

▲

-0.19

(-2.98%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Karyopharm Therapeutics share price in Dollar and Rupees. Guide to invest in Karyopharm Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Karyopharm Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Karyopharm Therapeutics share price movements

Today's Low: $5.93
Today's High: $6.62
$6.18
4.05%
Downside
Day's Volatility :10.42%
Upside
6.65%
52 Weeks Low: $6.18
52 Weeks High: $25.50
$6.18
0.0%
Downside
52 Weeks Volatility :75.76%
Upside
75.76%

Karyopharm Therapeutics (KPTI) Returns

Period	Karyopharm Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-46.68%	2.1%	0.0%
6 Months	-46.76%	-4.1%	0.0%
1 Year	-68.07%	2.2%	0.0%
3 Years	-92.99%	11.8%	-11.6%

Karyopharm Therapeutics (KPTI) Key Statistics

in dollars & INR

Previous Close	$6.37
Open	$6.43
Today's High	$6.62
Today's Low	$5.93
Market Capitalization	$53.6M
Today's Volume	$31.9K
52 Week High	$25.5
52 Week Low	$5.93
Revenue TTM	$145.2M
EBITDA	$-119.1M
Earnings Per Share (EPS)	$-13.95
Profit Margin	-52.62%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-891.05%

How to invest in Karyopharm Therapeutics Stock (KPTI) from India?

It is very easy for Indian residents to invest directly in Karyopharm Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Karyopharm Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Karyopharm Therapeutics or KPTI on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Karyopharm Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Karyopharm Therapeutics shares which would translate to 0.141 fractional shares of Karyopharm Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Karyopharm Therapeutics, in just a few clicks!

Returns in Karyopharm Therapeutics (KPTI) for Indian investors in Rupees

The Karyopharm Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Karyopharm Therapeutics investment value today

Current value as on today

₹35,940

Returns

₹64,060

(-64.06%)

Returns from Karyopharm Therapeutics Stock

₹69,023 (-69.02%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Karyopharm Therapeutics (KPTI)

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Karyopharm Therapeutics Stock from India on INDmoney has increased by 6% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Karyopharm Therapeutics

Vanguard Group Inc
6.06%
Adage Capital Partners Gp LLC
5.01%
Palo Alto Investors, LLC
3.89%
BlackRock Inc
2.99%
Morgan Stanley - Brokerage Accounts
2.78%
Citadel Advisors Llc
2.46%

Analyst Recommendation on Karyopharm Therapeutics

Buy

84%Buy

15%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Karyopharm Therapeutics(by analysts ranked 0 to 5 stars)

Based on 13 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Karyopharm Therapeutics Stock (KPTI)

What analysts predicted

Upside of 830.42%

Target:

$57.50

Current:

$6.18

Insights on Karyopharm Therapeutics Stock (Ticker Symbol: KPTI)

Price Movement
In the last 7 days, KPTI stock has moved down by -35.2%
Decreasing Revenue
Revenue is down for the last 3 quarters, 42.78M → 30.54M (in $), with an average decrease of 15.3% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -32.07M → -30.78M (in $), with an average increase of 4.2% per quarter
KPTI vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 128.2%
KPTI vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 140.5%
Price to Sales
ForKPTI every $1 of sales, investors are willing to pay $0.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

Karyopharm Therapeutics Technicals Summary

Sell

Neutral

Buy

Karyopharm Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Karyopharm Therapeutics (KPTI) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Karyopharm Therapeutics Inc	-31.47%	-46.76%	-68.07%	-92.99%	-98.05%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Karyopharm Therapeutics Inc	NA	NA	-0.15	-12.89	-8.91	-0.37	NA	-22.11
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Karyopharm Therapeutics Inc	Buy	$53.6M	-98.05%	NA	-52.62%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Organization	Karyopharm Therapeutics
Employees	279
CEO	Mr. Richard A. Paulson M.B.A.
Industry	Health Technology

Management People of Karyopharm Therapeutics

Name	Title
Mr. Richard A. Paulson M.B.A.	President, CEO & Director
Ms. Sohanya Cheng M.B.A.	Executive VP, Chief Commercial Officer & Head of Business Development
Mr. Stuart Poulton	Executive VP & Chief Development Officer
Dr. Reshma Rangwala M.D., Ph.D.	Executive VP, Chief Medical Officer & Head of Research
Dr. Mansoor Raza Mirza M.D.	Clinical Consultant, Member of Scientific Advisory Board & Independent Director
Dr. Sharon Shacham M.B.A., Ph.D.	Co-Founder & Chairman of Scientific Advisory Board
Ms. Kristin Abate	VP, Chief Accounting Officer & Assistant Treasurer
Mr. Brendan Twohig Strong	SVP of Investor Relations & Corporate Communications
Mr. Michael J. Mano J.D.	Senior VP, General Counsel & Secretary
Mr. James Accumanno J.D.	Chief Compliance Officer

Important FAQs about investing in KPTI Stock from India :

What is Karyopharm Therapeutics share price today?

Karyopharm Therapeutics share price today stands at $6.18, Open: $6.43 ; Previous Close: $6.37 ; High: $6.62 ; Low: $5.93 ; 52 Week High: $25.50 ; 52 Week Low: $6.18.

The stock opens at $6.43, after a previous close of $6.37. The stock reached a daily high of $6.62 and a low of $5.93, with a 52-week high of $25.50 and a 52-week low of $6.18.

Can Indians buy Karyopharm Therapeutics shares?

Yes, Indians can invest in the Karyopharm Therapeutics (KPTI) from India.

With INDmoney, you can buy Karyopharm Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Karyopharm Therapeutics at zero transaction cost.

How can I buy Karyopharm Therapeutics shares from India?

It is very easy to buy Karyopharm Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Karyopharm Therapeutics (KPTI) be purchased?

Yes, you can buy fractional shares of Karyopharm Therapeutics with INDmoney app.

What are the documents required to start investing in Karyopharm Therapeutics stocks?

To start investing in Karyopharm Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.